Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis and a full range of neurodegenerative diseases. Its first product, currently in development and anticipated for launch in 2019, will employ biomarker solutions, patient tracking tools and MRI optimization to provide neurologists and MS patients robust, objective metrics to facilitate informed care and shared decision making for better patient outcomes. Octave Bioscience is headquartered in Menlo Park, California, and is funded by BCBS Venture Partners, Echo Health Ventures, Section 32 and several private investors.